14-3-3 in the cerebrospinal fluid of patients with variant and sporadic Creutzfeldt-Jakob disease measured using capture assay able to detect low levels of 14-3-3 protein

Neurosci Lett. 2002 May 10;324(1):57-60. doi: 10.1016/s0304-3940(02)00172-6.

Abstract

A protein capture assay was used to measure 14-3-3 (-isoform) in the cerebrospinal fluid (CSF) of patients with either variant or sporadic Creutzfeldt-Jakob disease (CJD). The results were compared with those obtained using Western blotting. Elevated levels of 14-3-3 were found in 58% of variant CJD (vCJD) patients and 82% of sporadic CJD (spCJD) patients using the protein capture assay. Using a Western blotting technique, the presence of CSF 14-3-3 was detected in 58% of vCJD patients and in 89% of spCJD patients. When the results from the protein capture assay and the Western blot were combined, 14-3-3 was detected in 77% of vCJD patients and in 91% of spCJD patients. These results suggest that although analysis of CSF 14-3-3 is not as useful in vCJD as it is in the sporadic form of the disease, a combination of these two techniques results in increased sensitivity of 14-3-3 for the diagnosis of vCJD.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 14-3-3 Proteins
  • Aged
  • Amino Acid Motifs / physiology
  • Biological Assay / methods
  • Biomarkers
  • Blotting, Western
  • Brain / metabolism*
  • Brain / pathology
  • Brain / physiopathology
  • Creutzfeldt-Jakob Syndrome / cerebrospinal fluid*
  • Creutzfeldt-Jakob Syndrome / diagnosis*
  • Creutzfeldt-Jakob Syndrome / physiopathology
  • Diagnosis, Differential
  • Female
  • Humans
  • Male
  • Middle Aged
  • Neurons / metabolism*
  • Neurons / pathology
  • Predictive Value of Tests
  • Reproducibility of Results
  • Statistics as Topic
  • Tyrosine 3-Monooxygenase / cerebrospinal fluid*
  • Up-Regulation / physiology*

Substances

  • 14-3-3 Proteins
  • Biomarkers
  • Tyrosine 3-Monooxygenase